FV100 as a new approach for the possible treatment of varicella-zoster virus infection

McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X and Balzarini, J. 2009. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. Journal of Antimicrobial Chemotherapy 64 (4) , pp. 671-673. 10.1093/jac/dkp294

Full text not available from this repository.

Abstract

FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro-drug of Cf1743, the lead clinical candidate among the highly lipophilic bicyclic nucleoside analogue (BCNA) family discovered in Cardiff/Leuven. Cf1743 is unique amongst antivirals in terms of its structure and lipophilicity. It is exquisitely potent and selective for human VZV. FV100 has recently entered a randomized, controlled Phase II clinical trial for the treatment of shingles, sponsored by Inhibitex.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords:	Cf1743; BCNA; VZV; antiviral nucleoside
Publisher:	Oxford University Press
ISSN:	0305-7453
Last Modified:	17 Oct 2022 10:03
URI:	https://orca.cardiff.ac.uk/id/eprint/6637

Citation Data

Cited 15 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item